Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug duo tame Triple-Negative breast cancer?

NCT ID NCT06471205

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining BL-B01D1, a targeted drug, with a PD-1 monoclonal antibody can shrink tumors in people with advanced triple-negative breast cancer that cannot be surgically removed or has spread. The study enrolls about 52 adults aged 18 to 75 who have not had prior systemic therapy for their advanced disease. Researchers are measuring how many patients respond to the treatment and how long the benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of BL-B01D1 (izalontamab brengitecan) and a PD-1 monoclonal antibody
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced triple-negative breast cancer, a disease with limited therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. Combination therapies can also increase the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.